Host Responses to Intestinal Microbial Antigens in Gluten-Sensitive Mice by Natividad, Jane M. et al.
Host Responses to Intestinal Microbial Antigens in
Gluten-Sensitive Mice
Jane M. Natividad
1, Xianxi Huang
1, Emma Slack
1, Jennifer Jury
1, Yolanda Sanz
2, Chella David
3,
Emmanuel Denou
1, Pinchang Yang
4, Joseph Murray
5, Kathy D. McCoy
1., Elena F. Verdu ´
1.*
1Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Canada, 2Institute of Agrochemistry and Food Technology (IATA), Spanish
National Research Council (CSIC), Valencia, Spain, 3Department of Immunology, Mayo Clinic, Rochester, Minnesota, United States of America, 4Department of Pathology,
McMaster University, Hamilton, Canada, 5Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota, United States of America
Abstract
Background and Aims: Excessive uptake of commensal bacterial antigens through a permeable intestinal barrier may
influence host responses to specific antigen in a genetically predisposed host. The aim of this study was to investigate
whether intestinal barrier dysfunction induced by indomethacin treatment affects the host response to intestinal microbiota
in gluten-sensitized HLA-DQ8/HCD4 mice.
Methodology/Principal Findings: HLA-DQ8/HCD4 mice were sensitized with gluten, and gavaged with indomethacin plus
gluten. Intestinal permeability was assessed by Ussing chamber; epithelial cell (EC) ultra-structure by electron microscopy;
RNA expression of genes coding for junctional proteins by Q-real-time PCR; immune response by in-vitro antigen-specific T-
cell proliferation and cytokine analysis by cytometric bead array; intestinal microbiota by fluorescence in situ hybridization
and analysis of systemic antibodies against intestinal microbiota by surface staining of live bacteria with serum followed by
FACS analysis. Indomethacin led to a more pronounced increase in intestinal permeability in gluten-sensitized mice. These
changes were accompanied by severe EC damage, decreased E-cadherin RNA level, elevated IFN-c in splenocyte culture
supernatant, and production of significant IgM antibody against intestinal microbiota.
Conclusion: Indomethacin potentiates barrier dysfunction and EC injury induced by gluten, affects systemic IFN-c
production and the host response to intestinal microbiota antigens in HLA-DQ8/HCD4 mice. The results suggest that
environmental factors that alter the intestinal barrier may predispose individuals to an increased susceptibility to gluten
through a bystander immune activation to intestinal microbiota.
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Introduction
Celiac disease (CD) is an immune-mediated enteropathy
triggered by the ingestion of gluten containing cereals, and in
particular gliadin, the storage protein in wheat. It has recently
been recognized that both the pathology and the clinical spectrum
of CD varies considerably from severe to subtle, and that the
clinical expression is not restricted to the presence of mucosal
atrophy [1,2]. The concept of gluten sensitivity (GS) incorporates a
variety of pathologic, immunological, and clinical scenarios that
may, or may not, form part of the ‘‘celiac’’ spectrum such as
gluten-sensitive diarrhea, immunological mucosal response to
gluten in family members of celiac disease, persistent positive
specific serology for celiac disease in the absence of defined
enteropathy, and subtle immunopathological changes in the
intestine exposed to gluten. Typically, these disorders occur in
individuals who carry the same HLA genotypes associated with
celiac disease-DQ2 and DQ8 [3–7]. This has led to the
development of animal models of gluten-sensitivity that mimic
certain aspects of gluten-induced pathogenesis [8]. HLA-DQ8/
HCD4 or single HLA-DQ8 transgenic mice that are sensitized
with gluten develop an immune response to gliadin that involves
both the adaptive and innate immune system [8–11]. Although
these gluten-sensitive mice do not spontaneously develop intestinal
atrophy, they exhibit gluten-dependent changes in gut neuromus-
cular and epithelial secretory function [11]. This model has proven
useful for the preclinical testing of novel experimental therapies
designed to block gluten-induced mucosal pathology [12].
The presence of HLA-DQ2/DQ8 genes are necessary but not
sufficient for the development of CD [13], as up to 25–40% of
general populations in United States carry these genes and eat
gluten, but do not develop a celiac lesion [2,13], thus raising the
possibility of contributing environmental and genetic risk factors yet
to be identified [14]. The net availability of gliadin to the lamina
propria seems to be an important factor in the inflammatory
response of celiac patients. The immobilization and haptenation of
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transglutaminase aids and allows reservoirs of antigenically
potentiated gluten components to reach increased concentrations
in vivo, and may even induce a widespread mucosal response against
auto-antigens [15]. Indeed, celiac patients have been shown to
increase systemic titres of IgA antibodies against collagen [15].
Under normal conditions, the intestinal epithelium acts as a
protective barrier restricting transport of luminal antigens, and
only allows small and selective quantities to permeate the mucosa
[16–18]. In contrast, increased intestinal permeability has been
demonstrated in patients with active CD [19,20] and their healthy
relatives, suggesting that in a proportion of cases, intestinal barrier
abnormalities may predate overt inflammation [21]. Altered
barrier function could be a critical step in facilitating the host
responses that contribute to the clinical expression of gluten
sensitivity. Thus, the present study was designed to investigate
whether alteration of intestinal barrier function using the non-
steroidal anti-inflammatory drug (NSAID), indomethacin, enhanc-
es gluten-induced epithelial injury and influences subsequent host
responses to gut luminal antigens. Our results show that
indomethacin enhances gluten-induced changes in the mucosa
leading to increased IFN-c release by gliadin-stimulated spleno-
cytes and to systemic priming against intestinal microbiota
antigens. In genetically predisposed hosts with long standing
barrier abnormalities, this mechanism may lower the threshold of
inflammatory responses to specific antigens.
Results
Gluten sensitization and indomethacin treatment led to
retardation of weight gain
Gluten sensitized mice and non-sensitized mice treated with
indomethacin exhibited a mild retardation of weight gain after 7
weeks compared to non-sensitized controls. Gluten-sensitized mice
treated with indomethacin exhibited a more severe retardation of
weight gain after 7 weeks, compared to all groups (Figure S1).
These results suggest delayed thriving in mice treated with both
gluten and indomethacin.
Indomethacin increased tissue conductance and
permeation of macromolecules across epithelium in
gluten-sensitized mice
In order to determine the effects of gluten sensitization and
indomethacin treatment on intestinal permeability, tissue conduc-
tance and HRP flux were measured in segments of small intestine.
Gluten-sensitized mice treated with indomethacin exhibited a
significant increase in small intestinal tissue conductance com-
pared to non-sensitized controls and indomethacin alone-treated
mice (Figure 1A). HRP flux, a measurement of transcellular
macromolecular transport, was elevated in all groups compared to
non-sensitized controls. Gluten sensitization and indomethacin
treatment, however, led to the highest increase in HRP flux with
approximately 2.5 fold increase compared non-sensitized controls
(Figure 1B). The potentiation of intestinal permeability changes by
indomethacin was not observed in C57BL/6 mice sensitized with
gluten, stressing the importance of the DQ8 transgene in the
model (Figure S2).
Indomethacin led to epithelial ultra-structural damage in
gluten-sensitized mice
Intestinalmorphologywasanalyzedusingelectronmicroscopy.No
mitochondrial abnormalities were detected in non-sensitized controls
or in gluten-sensitized mice without indomethacin (Figure 2A,B).
Mitochondrial abnormalities were observed in mice treated with
indomethacin alone (Figure 2C) and in gluten-sensitized mice treated
with indomethacin (Figure 2D). We quantified the proportion of
mitochondria with disrupted cristae in a defined area with
Figure 1. Intestinal barrier measurements. Ussing-chamber experiments were performed on jejunum from all four groups 24 hours after the
last gluten challenge. (A) Gluten-sensitized mice treated with indomethacin showed a significant increase in tissue conductance. (B) HRP flux
(transcellular permeability) increased significantly in all treatment groups compared to non-sensitized controls, however the highest values were
observed in gluten plus indomethacin treated mice. Data represent the means6SEM of 10 mice/group.
doi:10.1371/journal.pone.0006472.g001
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Gluten-sensitized mice treated with indomethacin, had a higher
proportion of damaged mitochondria than gluten-sensitized mice
without indomethacin. Epithelial cell edema and disrupted microvilli
were observed in tissues obtained from gluten-sensitized plus
indomethacin treated mice but not from the rest of the groups
(Figure 3). These marked ultra-structural changes were not observed
in gluten-sensitized (Figure 3C) and indomethacin alone-treated mice
(Figure 3D). Altered junctional ultra-structure was more pronounced
in tissues from gluten-sensitized plus indomethacin-treated mice
(Figure 3E–G) compared to non-sensitized (A–B), gluten-sensitized
(C) and indomethacin alone-treated mice (D).
Concomitant treatment with indomethacin and gluten
led to reduction of E-cadherin mRNA expression
The changes in the ultra-structure of the tight junctions
prompted us to investigate whether there were alterations in
RNA expression of epithelial adherens and tight junctional
proteins. Gluten-sensitized and indomethacin alone-treated mice
showed reduced E-cadherin RNA expression by a mean factor of
0.762 and 0.533 respectively, but this did not achieve statistical
difference relative to non-sensitized controls (Figure 4). In contrast,
expression of E-cadherin RNA was markedly down regulated by
2.75 fold compared to non-sensitized mice, in gluten-sensitized
plus indomethacin-treated mice. Gluten sensitization and indo-
methacin did not affect significantly the relative RNA expression
of tight junction ZO-1 (Figure S3).
Indomethacin treatment affected the release of IFN-c by
splenocytes from gluten-sensitized mice after in vitro
challenge with PT-gliadin
In order to assess whether the increase in permeability and the
damage to the intestinal structure in gluten-senstized mice after
treatment with indomethacin led to an increase in the systemic
immune response to gliadin, we analyzed antigen-specific
proliferation and cytokine production of splenocytes. Increased
T cell proliferation after incubation with PT-gliadin was observed
in gluten-sensitized mice, but not in non-sensitized controls
(Figure 5). Differences in proliferation did not reflect cell death
or an inability to proliferate as polyclonal stimulation with ConA
led to equal responses in all groups (data not shown). Surprisingly,
indomethacin-treatment of gluten-sensitized mice did not exhibit
higher levels of antigen-specific proliferation compared to gluten-
sensitized mice that were not given indomethacin (Figure 5). In-
vitro incubation of splenocytes from gluten-sensitized mice with
indomethacin did not increase cell proliferation (Figure S4).
To further assess the systemic immune response IL-12, IFN-c and
IL-10 levels in the supernatant of the PT-gliadin stimulated splenocytes
cultures were determined (Figure 6). Whilst IL-12 was not induced
above media alone, IL-10 levels were slightly increased in the culture
supernatant of splenocytes from gluten-sensitized and indomethacin-
treated gluten-sensitized splenocytes after in vitro stimulation with PT-
gliadin, although the increases were not statistically significant.
In contrast, indomethacin treatment of gluten-sensitized mice led to
a significant increase in IFN-c production in response to PT-gliadin
stimulation. In-vitro incubation of splenocytes from gluten-sensitized
mice with indomethacin did not increase IFN-cproduction (Figure S5).
Gluten and indomethacin led to changes in intestinal
microbiota composition
We next analyzed whether gluten sensitization or indomethacin
treatment could lead to changes in the composition of the
intestinal microflora. Gluten-sensitized mice showed a significant
decrease of gut bacterial proportions of E. coli and E. rectale-
Clostridium groups, as compared to control mice. Indomethacin-
treated mice also showed reductions in E. coli proportions, but
increases in those of Bacteroides-Prevotella group. Gluten-sensitized
mice treated with indomethacin showed the most remarkable
alterations in the intestinal microbiota, characterized by reduc-
Figure 2. Evaluation of mitochondrial disruption. Mitochondrial ultra-structure was assessed by electron microscopy. Indomethacin increased
the fraction of disrupted mitochondria. Gluten sensitization plus indomethacin treatment further increased the proportion of altered mitochondria.
Data represent the means6SEM of 6 mice/group. Reperesentative pictures from (A) Control mouse, arrow: normal mitochondria; (B) Gluten-
sensitized mouse; (C) Indomethacin-treated mouse, arrowhead: mitochondria with disrupted cristae; (D) Indomethacin-treated plus gluten-sensitized
mouse, arrowhead: mitochondria with disrupted cristae.
doi:10.1371/journal.pone.0006472.g002
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from all groups 24 hours after the last gluten challenge. Gluten-sensitized and indomethacin alone-treated mice showed a trend for decreased
expression of E-cadherin relative to non-sensitized controls. Gluten-sensitized plus indomethacin-treated mice showed marked down-regulation of E-
cadherin RNA level relative to non-sensitized controls. Data represent the means6SEM of 6 mice/group.
doi:10.1371/journal.pone.0006472.g004
Figure 3. Apical epithelial cell structural abnormalities. Epithelial ultra-structure was assessed by electron microscopy. A significant
proportion of altered TJ was observed in gluten-sensitized plus indomethacin-treated mice. Indomethacin alone also increased the proportion of
altered TJ but to a lesser extent than indomethacin plus gluten. Gluten sensitization alone tended to increase the proportion of altered TJ but this did
not achieve statistical significance (p=0.09 vs non-sensitized controls). Data represent the means6SEM of 5 mice/group. Representative pictures of
(A–B) a control mouse, arrow: tight junction (TJ) with preserved structure; (C) Gluten-sensitized mouse, arrow: TJ with preserved structure; (D)
Indomethacin-treated mouse showing one altered TJ (arrowhead) and 2 junctions with normal struture (arrows); (E–G) Gluten plus indometacin
treated mouse; (E) arrowhead: microvilli (mv) height reduction, arrow: apical epithelial cell destruction; (F) Altered TJ, arrow: mitochondria (m) with
disrupted cristae; (G) Several altered TJs.
doi:10.1371/journal.pone.0006472.g003
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PLoS ONE | www.plosone.org 4 July 2009 | Volume 4 | Issue 7 | e6472Figure 5. Splenocyte proliferation after incubation with PT gliadin. Proliferation was measured by
3H-thymidine incorporation and
expressed as stimulation index. Splenocytes from gluten-sensitized mice treated with or without indomethacin exhibited increased proliferation
compared to non-sensitized controls. Data represent the means6SEM of 6 mice/group.
doi:10.1371/journal.pone.0006472.g005
Figure 6. Cytokines in supernatant of splenocyte cultures after incubation with PT-gliadin (black) or medium (white). Expressions of
(A) IL-12p70, (B) IFN-c, (C) IL-10 were determined by CBA analysis. Culture supernatants from gluten-sensitized plus indomethacin (Indo) treated mice
showed increased IFN- c (*p,0.01 vs all groups). Cultured splenocytes from gluten-sensitized mice, with or without indomethacin showed a trend for
increased IL-10 release after PT-gliadin stimulation (p=0.09). Data represent the means6SEM of 6 mice/group.
doi:10.1371/journal.pone.0006472.g006
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compared with control mice (Figure 7).
Indomethacin led to systemic priming against intestinal
microbiota in gluten-sensitized mice
Previous data suggests that bacterial translocation beyond the
mucosal immune system is necessary for systemic priming to
intestinal commensals [26]. To determine if the increased
conductance and HRP flux induced by gluten-sensitization and
indomethacin was accompanied by loss of the host’s normal
systemic ignorance to the intestinal microbiota, we measured
specific IgM antibody responses to culturable aerobic or anaerobic
commensals. Non-sensitized mice showed no evidence of IgM
specific antibodies against aerobic and anaerobic commensal flora
as assessed by flow cytometric analysis of anti-bacterial IgM
responses (Figure 8 & Figure S6). Treatment with either gluten or
indomethacin alone led to the production of very low titres of IgM
antibodies directed against a subset of culturable bacteria. Gluten
sensitization plus indomethacin treatment, however, resulted in
induction of strong specific IgM responses directed against 40–80%
of culturable bacteria. The anti-bacterial IgM induced was specific
to the commensal microflora of the host and did not bind to
Salmonella, which these mice have never been exposed to (Figure
S7).These data indicate that the combination of gluten-sensitization
and increased intestinal permeability as induced by indomethacin
treatment increased systemic priming to the commensal microflora.
Discussion
The aim of this study was to investigate whether modulation of
the intestinal barrier by an environmental trigger can affect host
responses to luminal antigens in a genetically predisposed host.
Our results demonstrate that gluten sensitization and long-term
gluten challenge in HLA-DQ8/HCD4 mice alters intestinal
permeability as assessed by increased transcellular macromolecu-
lar transport and a tendency for higher conductance values
(paracellular pathway). This is in agreement with previous reports
showing that gluten peptides have the ability to rapidly disrupt the
apical junctional structure [22–25], and can also be transported by
an abnormal transcellular route [26]. Administration of indo-
methacin to gluten-sensitized mice led to more pronounced barrier
dysfunction, which was accompanied by a mild pro-inflammatory
shift with marked changes in EC ultra-structure, reduced E-
cadherin mRNA levels in the proximal small intestine and
generation of systemic antibody responses to intestinal microbiota.
Indomethacin has been used at higher doses as a model of
inflammatory bowel disease (IBD) [27,28], and has been shown to
compromise epithelial barrier integrity and function, induce
motility changes, and promote small intestinal bacterial over-
growth and translocation [27,29]. In the present manuscript, low-
dose indomethacin induced permeability changes without pro-
ducing macroscopic or microscopic ulcers. However, ultra-
structural observations revealed epithelial cell abnormalities
characterized by mitochondria with disrupted cristae in mice
receiving indomethacin. Mucosal toxicity induced by gluten in
HCD4/DQ8 mice was potentiated by indomethacin, as shown by
more marked elevation of HRP flux and a significant increase in
tissue conductance. After administration of indomethacin,
C57BL/6 mice exhibited increased HRP flux, but no change in
tissue conductance. Gluten sensitization however, did not induce
barrier dysfunction in C57Bl6 mice, emphasizing the relevance of
the DQ8 transgene in the model (Figure S2). Electron microscopy
Figure 7. Microbiota composition. Using 9 different oligonucleotide probes and fluorescent in situ hybridization (FISH), microbial profile was
investigated in the distal jejunum of sensitized mice with and without indomethacin. The results indicate a significant perturbation in the proportions
of microbiota investigated in all 3 treatment-groups when compared to non-sensitized controls, and remarkably in the gluten-sensitized plus
indomethacin group. These differences achieve statistical significance in Bifidobacteria (*p=0.04 vs controls, +p=0.03 vs gluten) and Clostridium
Leptum cluster (both *p=0.02 vs controls and gluten sensitized, **p=0.04 vs indomethacin) compared to gluten-sensitized alone. Data represent the
means6SEM of 6 mice/group.
doi:10.1371/journal.pone.0006472.g007
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indomethacin revealed more structural abnormalities in the apical
region of the epithelium compared to gluten alone-treated mice.
Furthermore, RT-PCR analysis demonstrated reduced E-cadherin
RNA levels in gluten-sensitized plus indomethacin treated mice. E-
cadherin is required for TJ formation and there is growing
evidence for its role as modulator of TJ and intestinal barrier
function [30,31]. E-cadherin expression is reduced in children
with CD and gliadin has been shown to alter its expression [32].
Our results support the hypothesis that both gluten and
indomethacin play a role in the expression of E-cadherin, and
that this effect is potentiated in a genetically susceptible host when
both agents are administered together. Marked reduction of E-
cadherin may constitute a mechanism for the enhanced barrier
dysfunction observed in gluten-sensitized and indomethacin-
treated HCD4/DQ8 mice.
The marked changes in barrier function in gluten-sensitized plus
indomethacin-treated mice were accompanied by increased IFN-c
production in splenocyte cultures after incubation with PT-gliadin.
These results suggest a shift towards a mild systemic pro-inflammatory
state. Previous studies have shown that cyclooxygenase-2 (COX-2)-
dependent arachidonic acid metabolites are important in the
maintenance of intestinal immune homeostasis, particularly in the
immunoregulation of dietary antigens [33]. Consequently, COX-2
inhibitors such as indomethacin may exacerbate the immune response
to dietary antigens [33]. Our results using in vitro incubation of
splenocytes with PT gliadin and indomethacin, however, do not
support a direct effect of indomethacin on splenocyte proliferation and
IFN-c release. Thus, we hypothesize that the shift in the immune
response may be due to an enhanced uptake of luminal contents,
including commensal bacteria, through a more structurally damaged
and permeable epithelium.
The intestinal epithelium regulates permeation of luminal
antigens and excessive immune activation within the mucosa
[16,34]. The marked barrier defect in gluten-sensitized mice
treated with indomethacin may not only allow an increased influx
of gliadin peptides across the epithelium but also of other luminal
antigens such as intestinal microbiota with potential bystander,
pro-inflammatory effects. Germ-free rats have been reported to
have a higher threshold for intestinal damage after indomethacin
administration compared to specific pathogen-free (SPF) rats [35].
Since inhibition of prostaglandins in the absence of an intestinal
Figure 8. Systemic antibodies against commensals. Serum from indomethacin and gluten treated mice showed significant positive serum
antibodies against their aerobic and anaerobic intestinal microbiota. (A) Representative FACS histogram from each treatment gated on IgM
+ cells; (B)
Proportion of IgM
+ aerobic bacterial cells for each treatment groups; (C) Proportion of IgM
+ anaerobic bacterial cells for each treatment groups. Data
represent the means6SEM of 6 mice/group.
doi:10.1371/journal.pone.0006472.g008
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intestinal bacteria potentiate the development of indomethacin-
induced mucosal lesions. Thus, dysmotility induced by gluten
sensitization [11] or indomethacin [36], and/or the ability of
indomethacin to induce small intestinal dysbiosis [36,37] may
facilitate bacterial translocation. Due to a severely impaired
intestinal barrier in both gluten-sensitized and indomethacin-
treated mice, increased permeation of luminal bacteria may
disturb the natural commensal homeostasis in the gut promoting a
pro-inflammatory response. SPF mice have been shown to be
systemically ignorant to their intestinal microbiota due to the
geographic and functional separation between the mucosal and
systemic immune system by the mesenteric lymph nodes (MLN)
[17,38]. Our results show, however, that a low level of systemic
priming against intestinal microbiota occurs in SPF mice treated
with either gluten or indomethacin alone. Gluten-sensitized mice,
in which barrier function is further perturbed by indomethacin
treatment, show dramatic systemic priming to their intestinal
microbiota. These data therefore imply that gluten-sensitization, in
combination with indomethacin treatment, results in decreased
mucosal containment of the commensal flora. NSAIDs have been
shown to reduce the phagocytic properties of macrophages [39].
Thus, we acknowledge that it is possible that in addition to
changes in intestinal barrier function, indomethacin may have a
dual effect by inhibiting macrophage function, allowing the
persistence of live bacteria, and facilitating a systemic immune
response against intestinal microbiota. F4/80
+ cell counts in the
lamina propria of gluten plus indomethacin-treated mice were
significantly increased (Figure S8, Protocol S1), however macro-
phage function was not assessed. The exact identities of the
commensals to which gluten and indomethacin-treated mice are
systemically primed in this model are not yet known but the
absence of IgM binding to Salmonella, known to be absent from the
commensal flora of our mice, strongly suggests the specificity of the
IgM antibodies against commensal flora in our mice (Figure S7).
The clinical relevance of the loss of systemic ignorance against the
intestinal microbiota remains to be established, however, systemic
priming to the commensal flora represents a significant shift in the
normal relationship between host and commensal bacteria [40].
Consequently, this may indicate a novel mechanism that could
contribute to the progression of disease in a gluten-sensitive host.
On the other hand, specific IgM against flora may be part of a
protective mechanism mounted by the immune system to limit
subsequent translocation and widespread inflammation. Addition-
al host factors, such as an underlying immune dysbalance, may
play a role in determining whether this mechanism will become
maladaptive and contribute to widespread inflammation. A recent
epidemiological study has determined that consumption of non-
steroidal anti-inflammatory drugs (NSAIDs) is a risk factor for the
development of irritable bowel syndrome [41]. No epidemiological
studies to date have investigated whether a history of NSAID
consumption is also a risk factor for the protean clinical expression
in gluten sensitivity.
Although the role of the intestinal microbiota in other chronic
diseases of the gut is clearly established [for review see 42] little is
known about the role of abnormal immune responses to
commensals in gluten and other food intolerances. Recent
findings, however, report presence of rod-shaped bacteria in the
mucosa of active and non-active celiac patients but not in healthy
controls [43]. A study in patients with CD revealed the presence of
serological responses to microbial antigens, such as anti-Saccharo-
myces cerevisiae, anti-I2 (Pseudomonas fluorescens) and anti-ompW,
compared to healthy controls. Interestingly, microbial seropositiv-
ity was also present in gluten-sensitive patient with no evidence of
active CD. However, increasing age was associated with sero-
reactivity for anaerobic bacteria, possibly reflecting exposure to
different environmental antigens with longer duration of disease
[44]. The disappearance of anti-Saccaromyces cervisiae-antibodies
(ASCA) after a gluten-free diet suggests that healing of mucosal
lesions is related to microbial sero-markers [45]. However, a causal
relationship between gut dysfunction, symptoms and microbial
sero-responses in CD remains to be determined. It is possible that
accumulated bacterial products have a bystander effect and lower
the threshold for immune cell activation [46,47]. To this respect, a
study in DQ8 mice has shown that oral challenge with Lactobacillus
casei at the time of mucosal sensitization with gliadin and cholera
toxin exacerbates the Th1 response induced in the model [48].
Thus, it is possible that dysbiosis or shifts in the composition of the
intestinal microbiota at the time of gluten sensitization, and not
necessarily the presence of a pathogen, contribute to enhance
gluten-induced immune responses. An altered microbiota compo-
sition has been reported in patients with CD compared to healthy
controls [49,50]. In this study, we observed significant alterations
in the composition of the small intestinal microbiota in gluten-
sensitized mice treated with indomethacin. It is unclear, however,
if these changes are primary or secondary to the functional gut
abnormalities observed in the model [11].
In conclusion, our findings suggest that an environmental
alteration of the intestinal barrier plays a critical role in
determining host immune responses to gluten and intestinal
microbiota antigens. Bystander luminal antigens such as compo-
nents of the intestinal microbiota may contribute to enhance
inflammatory responses to dietary antigens such as gluten. This
mechanism may become important in genetically predisposed
hosts with longstanding barrier abnormalities. The results warrant
further investigations on the interactions between host genotype,
diet, and intestinal microbiota.
Materials and Methods
Animals
All experiments were conducted with approval from the
McMaster University Animal Care Committee. Male transgenic
mice expressing HLA-DQ8 genes (HLA-DQA1*0301; HLA-
DQb1*0302) in the absence of endogenous mouse class II genes
or HLA-DQ8/HCD4 double transgenic mice were used [8,51].
The mice were bred in a conventional specific pathogen free
colony (SPF) at McMaster University and maintained for at least 2
generations prior to breeding on a gluten-free diet (Bio-Serv, New
Jersey). Mice were used at the age of 8-14 weeks. Male C57BL/6
mice were purchased from Taconic (Hudson, NY, USA)
(supplementary data).
Sensitization protocol and indomethacin treatment
All mice were continuously fed with a gluten-free diet and water
available ad libitum.
Mice were sensitized by injecting intraperitoneally (ip) 500 mgo f
gluten (Sigma-Aldrich, Ontario) dissolved in 0.02 mM acetic acid
in 50 ml of Complete Freund’s Adjuvant (CFA, Sigma-Aldrich,
Ontario). One week after sensitization, gluten challenge was
performed 3 times on a weekly basis by intragastric gavage, for 7
weeks, using 2 mg of gluten dissolved in 0.02 mM acetic acid.
Indomethacin was administered by gavage (Ovation Pharmaceu-
ticals, Ontario) (3.5 mg/kg) 24 hours before the gluten challenge.
Control groups consisted of a) non-sensitized mice (CFA only)
subsequently gavaged with rice cereal (2 mg/0.02 mM acetic
acid), b) gluten-sensitized mice subsequently gavaged with gluten
NSAID and Gluten Sensitivity
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subsequently gavaged with indomethacin (3.5 mg/kg).
In vitro intestinal permeability
Two sections of jejunum from each mouse were used for Ussing
chamber studies. Briefly, 5 cm of jejunum samples were collected
and divided into 2 segments. Each segment was opened along the
mesenteric border, flattened and mounted in an Ussing chamber
with an opening of 0.6 cm
2. Tissues were bathed in oxygenated
Krebs buffer containing 10 mM glucose (serosal side) or 10 mM
mannitol (luminal side) at 37uC. After a 20-minute equilibration
period, conductance (G: mS/cm2) were recorded. Mucosal to
serosal transport of macromolecules was assessed by adding
horseradish peroxidase (HRP; type II, Sigma-Aldrich, Ontario), a
commonly used macromolecular marker, in the luminal side.
Serosal samples (500 ml) were obtained at 30 minutes intervals for
2 hours. Intact HRP was assessed using a modified Worthington
method with o-dianosidine dihydrochloride (Sigma-Aldrich, On-
tario) as the substrate, and mucosal to serosal fluxes were
calculated according to standard formulae and expressed as
pmol/cm
2/hr.
Examination of epithelial cell injury
Jejunal sections were obtained and immediately fixed in 2.5%
glutaraldehyde in 0.1 mol/L sodium cacodylate buffer (pH 7.4)
for 2 hours, transferred to sodium cacodylate buffer and stored at
4uC overnight. Tissues were subsequently processed for electron
microscopy, and photomicrographs were prepared. Ultra-struc-
tural epithelial damage was evaluated in enterocytes by the
presence of alterations in brush border, mitochondrial edema and
tight junction (TJ) morphology. Epithelial damage was determined
by transmission electron microscope (JEOL, Tokyo) of enterocytes
in sections from 4–6 animals in each of the 4 study groups. The
number of mitochondria with disrupted cristae within the apical
region of enterocytes were counted on coded 5000x magnification
photomicrographs measuring a total of 300 mm
2 (125–250
mitochondria/photomicrographs, 5 photomicrographs/mouse,
6 mice/group) using Adobe CS3 Extended (Adobe Systems
Incorporated, California). The fraction of altered mitochondria,
defined as number of mitochondria with disrupted cristae divided
by total number of mitochondria in a view, was calculated.
Mitochondria on the edge of micrographs were excluded for
evaluation, since neither their boundaries nor area could be
accurately determined. The fraction of disrupted TJ structure was
calculated as total altered TJ divided by total number of TJ
evaluated in 20 fields per mouse in a blinded manner (3–20 tight
junctions/field, 60–400 tight junctions/mouse, 4 mice/group). A
field is defined as one square in the EM grid, measuring
8100 mm
2.
Apical junctional analysis by quantitative real-time PCR
Total RNA from a 30–60 mg proximal small intestine section
was isolated using RNeasy mini kit (Qiagen, Ontario). cDNA was
synthesized from 2 mg of purified total RNA using M-MLV
reverse transcriptase (Invitrogen, Ontario). Quantitative real-time
PCR was performed with 1:20 dilutions of cDNA. The reaction
consisted of iQ
TM SYBR Green Supermix (Bio-rad, Ontario) for
quantitative PCR, primers at 0.5 mM, and 1 ml of cDNA.
Amplification was performed using iQ5 Real-Time Detection
System at 95uC for 3 min followed by 37 cycles at 94uC for 15 s,
55uC (ZO-1) or 58uC (E-Cadherin) or 59uC (GAPDH) for 20 s,
and 72uC for 25 s. Q Real-time PCR was performed using the
following primers: ZO-1 59-AGGACACCAAAGCATGTGT-
GAG-39/and 39-GGCATTCCTGCTGGTTACA-59;
E-Cadherin 59-GCACATATGTAGCTCTCATC-39 and 59C-
CTTCACAGTCACACACATG-39.G A P D H5 9-CCATGGAGA-
AGGCTGGGG-39 and 59-CAAAGTTGTCATGGATGACC-39
was used as housekeeping gene. CT values reported by iQ5 software
were used in the study. PCR efficiencies for each amplicon were
determined by making 10-fold serial dilutions of cDNA and then
amplifying the cDNA using primers to both the gene of interest and
housekeeping gene. Relative expression levels were calculated using
the Pfaffl method [52], with efficiency correction for each primer set,
using REST software [52]. A melting curve analysis was performed
by heating the reactions from 50u to 99uCi n0 . 2 uC intervals while
monitoring fluorescence.
Splenocyte proliferation, cell cultures and cytokine
analysis
Peptic-tryptic digests of gliadin (PT-gliadin) was prepared as
described previously [54]. Spleen cells were harvested and
cultured (4610
5 cells/well) in 96-well tissue culture plates at
37uC, 5% CO2 for 72 h in the presence or absence of 500 mg/ml
PT-gliadin and/or 5 mg/ml indomethacin. The cultures were
pulsed with 1 mCi/well [
3H]-thymidine for 18 h. The cultured
cells were harvested onto glass fibre filters using Filtermate
harvester (Cambridge Technology, Massachusetts). The radioac-
tivity incorporated was determined with a Beta Scintillation
Counter (Beckman, California). Results are expressed as stimula-
tion index (SI) and calculated as: SI=(mean cpm of triplicate
cultures containing antigen)/(mean cpm of cells cultured with
medium alone).
Splenocyte supernatants were collected 48 h after incubation
with or without PT-gliadin and/or indomethacin. The presence of
pro-inflammatory cytokines in the supernatant was measured
using pro-inflammatory CBA kit (BD Bioscience, California) and
analyzed using BD FACSarray Bioanalyzer System (BD Biosci-
ence, California).
Fluorescent in situ hybridisation (FISH)
Oligonucleotide probes are summarized in Table S1. The
group-specific probes were labeled at the 59-end with fluorescein
isothiocyanate (FITC), showing green fluorescence. EUB 338
probe, targeting conserved sequences within the bacterial domain,
was used as positive control [55]. NON EUB 338 probe was used
as negative control to eliminate the background fluorescence [56].
Both control probes were labelled at the 59end with either the
indocyanine dye Cy3, showing red fluorescence, or with FITC.
Aliquots of 36 ml fixed samples were incubated with 4 ml of each
fluorescent probe (50 ng/ml) in hybridization solution (10 mM
Tris–HCl, 0.9 M NaCl, pH 8.0, and 10% [w/v] sodium dodecyl
sulphate) at appropriate temperature (45–50uC) overnight. After-
wards, bacterial cells were incubated with 400 ml washing solution
(10 mM Tris–HCl, 0.9 M NaCl, pH 8.0) at 50 uC for 30 min to
remove non-specific binding of the probes. Hybridized cells were
finally pelleted by centrifugation (12 000 g for 5 min) and
resuspended in 400 ml of PBS for flow cytometry detection.
Bacterial groups were enumerated by combining each FITC-
labelled group-specific probe with the EUB 338-Cy3 probe, and
expressed as a ratio of cells hybridizing with the FITC-labelled
specific probe to cells hybridizing with the EUB 338-Cy3 probe.
This proportion was corrected by subtracting the background
fluorescence obtained with the negative control probe NON EUB
338 [57,58]. Flow cytometry detections were performed using
anEPICSH XL-MCL flow cytometer (Beckman Coulter, Florida,
USA) as previously described [58]. This instrument is equipped
with two light scatter detectors that measure forward (FSC) and
side scatter (SSC) and fluorescence detectors that detect appro-
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620 nm) wavelengths. The event rate was kept at the lowest setting
(200–300 events per second) to avoid cell coincidence. A total of
15, 000 events were recorded in a list mode file and analyzed with
the System II V.3 software (Beckman Coulter).
Statistical Analysis
Statistical analysis was performed using ANOVA with post-hoc
test for simple and multiple comparisons, respectively. Nonpara-
metric statistical significance of relative RNA expression was
calculated with REST software [53] by a pairwise fixed reallocation
randomization test with 50,000 repeats. Data were presented as
means6standard error (SEM).
Supporting Information
Figure S1 Weight gain over 7-week period. Both gluten-
sensitized and indomethacin treated mice exhibited a decreased
rate of weight gain compared to non-sensitized controls. Gluten-
sensitized mice treated with indomethacin exhibited more pro-
nounced weight gain retardation compared to controls and to
gluten-sensitized and indomethacin treated mice. Data represent
the means6SEM of 10 mice/group.
Found at: doi:10.1371/journal.pone.0006472.s001 (0.08 MB TIF)
Figure S2 Conductance and HRP flux in C57Bl/6 mice. Gluten
and/or indomethacin treatment did not lead to changes in tissue
conductance. HRP flux was increased in indomethacin treated
mice, but not in gluten sensitized mice without indomethacin.
Data represent the means6SEM of 10 mice/group.
Found at: doi:10.1371/journal.pone.0006472.s002 (0.09 MB TIF)
Figure S3 ZO-1 RNA expression relative to non-sensitized
controls. No significant differences were seen when RNA expression
for each treatment group was analyzed relative to non-sensitized
controls. Data represent the means6SEM of 6 mice/group.
Found at: doi:10.1371/journal.pone.0006472.s003 (3.00 MB TIF)
Figure S4 Splenocyte proliferation after incubation with PT-
gliadin and/or indomethacin. Stimulation with indomethacin
alone did not increase splenocyte proliferation in gluten-sensitized
mice. In-vitro stimulation with both PT-gliadin and indomethacin,
did not further enhance cell proliferation compared to PT-gliadin
alone. Data represent the means6SEM of 6 mice/group.
Found at: doi:10.1371/journal.pone.0006472.s004 (0.07 MB TIF)
Figure S5 IFN-c levels in supernatant of cultured splenocytes
after incubation with PT-gliadin and/or indomethacin. Stimula-
tion with indomethacin alone did not increase IFN-c production
in gluten-sensitized mice. In-vitro stimulation with PT-gliadin and
indomethacin did not increase IFN-c levels compared to PT
gliadin alone. Data represent the means6SEM of 6 mice/group.
ND=not detectable.
Found at: doi:10.1371/journal.pone.0006472.s005 (0.07 MB TIF)
Figure S6 Systemic antibodies against commensals. Gluten-
sensitized plus indomethacin-treated mice exhibited increased
serum antibodies against aerobic and anaerobic bacteria as
assessed by median fluorescent intensity signal of APC-labelled
anti-IgM (1:20 serum dilution). Negative controls include serum
(2): no serum and bacteria (2): no bacteria. Data represent the
means6SEM of 6 mice/group.
Found at: doi:10.1371/journal.pone.0006472.s006 (0.11 MB TIF)
Figure S7 Positive and negative systemic antibodies against
commensals. (A) Salmonella M557, which is a pathogen not present
in our HLA-DQ8/HCD4 mice colony, was stained with serum
antibodies from indomethacin plus gluten treated mice. Results show
the absence of positive antibodies against Salmonella, thus the
specificity of the technique. (B) Salmonella M557 was stained with
serum antibodies from Salmonella M557 infected mice. Results show
the absence of positive antibodies against Salmonella.
Found at: doi:10.1371/journal.pone.0006472.s007 (0.09 MB TIF)
Figure S8 Immunohistochemistry for F4/80+ cells. Staining for
F4/80+ was increased in gluten sensitized mice. Infiltration of F4/
80+ cells was most marked in gluten-sensitized mice treated with
indomethacin. Data represent the means6SEM of 6 mice/group.
Representative picture of macrophage infiltration in the lamina
propria from (A) control mice (B) gluten-sensitized mice (C)
indomethacin-treated mice (D) gluten-sensitized plus indometha-
cin treated mice.
Found at: doi:10.1371/journal.pone.0006472.s008 (0.47 MB TIF)
Table S1 Oligonucleotide probes and hybridization conditions
used in FCM-FISH analysis of intestinal bacteria.
Found at: doi:10.1371/journal.pone.0006472.s009 (0.06 MB
DOC)
Protocol S1 Immunohistochemistry for macrophages.
Found at: doi:10.1371/journal.pone.0006472.s010 (0.03 MB
DOC)
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